High-Level Vancomycin-Resistant Staphylococcus aureus (VRSA) in Iran: A Systematic Review

  • Emran Askari Mashhad Medical Microbiology Student Research Group, Mashhad University of Medical Sciences, Mashhad, IR Iran AND Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  • Ahmadreza Zarifian Mashhad Medical Microbiology Student Research Group, Mashhad University of Medical Sciences, Mashhad, IR Iran AND Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran.
  • MohammadReza Pourmand Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran.
  • Mahboobeh Naderi-Nasab Mashhad Medical Microbiology Student Research Group, Mashhad University of Medical Sciences, Mashhad, IR Iran AND Department of Medical Bacteriology and Virology, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran.
Iran, Vancomycin Resistance, Staphylococcus aureus


Background: Staphylococcus aureus is a major human pathogen world wide. Vancomycin has been used for decades to treat multidrug resistant S. aureus. Ten years has passed since the first report of vancomycin re sistant S. aureus (VRSA). The objective of this systematic review was to determine  the total number of VRSA isolates that have been reported from Iran.Methods:  Search terms reflected “Iran”, “vancomycin” and “S. aureus” were  searched  in the ISI web  of knowledge,  PubMed,  SciVerse,  and Google scholar. Also two Persian scientific databases and 13 recent na tional congresses  were investigated.  Articles / abstracts working on S. aureus in Iran, evaluating vancomycin MIC and / or PCR of vanA/B were included in this systematic review.Results: Out of the 3484 records found in mentioned resources, 13 related studies were included in the final analysis. The result showed that at least 24 VRSA isolates which have been reported from Iran up to September 2012.Conclusion: It seems that many Iranian researchers did not follow a spe cific guideline for reporting and confirming VRSA. Establishing an Iranian reference center where studies on VRSA can be registered, evaluated and confirmed is strongly recommended.


Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, et al. National trends in Staphylo- coccus aureus infection rates: impact on economic burden and mortality ov er a 6 year period (1998-2003). Clin Infect Dis 2007; 45: 1132-40.

Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant an d methicillin-susceptible Staphylococc us aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36 (1): 53-9.

Van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staph ylococcus aureus bacteremia. Clin Mi crobiol Rev 2012; 25 (2): 362-86.

Jevones MP. Celbenin-resistance staphylococci. Br Med J 1961; 1: 124-5.

Grundmann H, Aires-de-Sousa M, B oyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a publiche alth threat. Lancet 2006; 368 (9538): 874- 85.

Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Meticillin-resistant Staphyloco ccus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012; 39 (4): 273-82.

Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Sta phylococcus aureus. Emerg Infectdis 2001; 7(2): 327-32.

Noble WC, Virani Z, Cree RG. Cotransfer of vancomycin and other resistance genes from Enterococcus fae calis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72 (2): 195-8.

Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomy cin susceptibility. J Antimicrob Chemother 1997; 40 (1): 135-6.

Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphy lococcus aureus, including vancomycin-intermediate and heteroge- neous vanco mycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23 (1): 99-139.

Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycinresistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348 (14): 1342.

Perichon B, Courvalin P. vanA-type vancomycin-resistant Staphylococcus . Antimicrob agents chemother 2009; 53 (11): 4580-7.

Levine DP. Vancomycin: a History. Clin Infect Dis 2006; 42 (1): S5-S12.

Perichon B, Courvalin P, 2012. Glycopeptide Resistance. In: Dougherty TJ, Pucci MJ. (Eds.), Antibiotic discovery and development, 1st ed. Springer, USA, New York, pp. 515-42.

Bugg TDH, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. Molecular basis for vancomycin resistance in Enterococcus faecium BM 4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins vanH and vanA. Biochemistry 1991; 30 (43): 10408-15.

Clinical and Laboratory Standards Institute. Performance standards for an- timicrobial susceptibility testing. 22nd informational supplement M100-S22, CLSI, Wayne, PA, 2012.

Tiwari HK, Sen MR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 2006; 6: 156.

Rahimi-Alang S, Amini A. Vanco- mycin resistant Staphylococcus au- reus: 2 isolates communication. The Abstract book of 5th Iranian Congress of Clinical Microbiology 8-10 No- vember 2011, Shiraz, Iran.

Saderi H, Owlia P, Shahrbanooie R. Vancomycin resistance among clinial isolates of Staphylococcus aureus. Arch Iran Med 2005; 8 (2): 100-3.

Mostafavizadeh K, Khorvash F, Mobasherizadeh S, Fasihi Dastjerdi M. Study of nosocomial Staphylococcus aureus resistance with E-test method. Journal of Medical Council of Islamic Republic of Iran 2007; 26 (4): 522-9.

Faghri J, Azimian A, Sadighian H, Khosrojerdi M. Occurance of the methicillin-resistant Staphylococcus aureus (MRSA) among respiratory tract samples in patients of selected Tehran hospitals. The Abstract book of 4th Iranian Congress of Clinical Microbiology. 9-11 November 2010, Isfahan, Iran.

Saderi H, Owlia P, Maleki Z, Habibi M, Rahmati N. Susceptibility to vancomycin in Staphylococcus aureus isolated from patients of four univer- sity-affiliated hospitals in Tehran. Iran J Pathol 2008; 3 (3): 161.

Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H. Emergence of high-level vancomy cin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 2008; 17 (5): 432-4.

Ghasemian R, Najafi N, Makhlough A, Khademloo M. Frequency of na-sal carriage of Staphylococcus aureus and its antimicrobial resistance pattern in patients on hemodialysis. IranJ Kidney Dis 2010; 4 (3): 218-22.

Alikhani A, Tiroum S, Khademloo M, Tayyebi ME, Shoujaiifar, Doudangeh M. A microbiological study and MIC determination of ventilatorassociated pneumonia causing agents in two university associated hospitals’ ICUs. Abstract book of the First Iranian International Congress of Medical Bacteriology. 5-8 September 20 11, Tabriz, Iran.

Sheikh Moniri S, Mubayen H, Mirzaee H, Munes Rast S. A study of vancomycin-resistance and identification of vanA gene in Staphylococcus aureus strains isolated from Tabriz Shuhada Hospital through E-test and PCR methods. First International and 12th Iranian Congress of Microbiology. 23-26 May 2011, Kermanshah, Iran.

Hosain Zadegan H, Menati S. The prevalence of methicillin and vancomycin resistant Staphylococcus aureus nasal carriage in large teaching hospital personnel. Afr J Microbiol Res 2011; 5 (22): 3716-9.

Anvari M, Ranji N, Khoshmaslak F.Antibacterial Susceptibility of Three Vancomycin-Resistant Staphylococc us aureus Strain Isolated from Nor thern Part of Iran. J Pure Appl Microbiol 2012; 6 (2): 671-5.

Dezfulian A, Aslani MM, Oskoui M, Farrokh P, Azimirad M, Dabiri H, et al. Identification and character ization of a high vancomycinresistan t Staphylococcus aureusharboring va nA gene cluster isolated from diabetic foot ulcer. Iran J Basic Med Sci 2012; 15: 803-6.

Azimian A, Havaei SA, Fazeli H, Na- deri M, Ghazvini K, Mirab Samiee S, et al. Genetic characterization of a vancomycin-resistant Staphylococcus aureus isolated from respiratory tract of a hospitalized patient in a university hospital in north east of Iran. J Clin Microbiol 2012; 50 (11): 3581-5.

Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characte- rization of glycopeptide-resistant Enterococci from U.S. hospitals. An- timicrob Agents Chemother 1993; 37 (11): 2311-7.

Van Hal SJ, Paterson DL. New gram- positive antibiotics: better than vancomycin. Curr Opin Infect Dis 2011; 24 (6): 515-20.

Gould IM. Clinical activity of anti-gr am-positive agents against methicillin resistant Staphylococcus aureus. J Antimicrob Chemother 2011; 66 (Suppl 4): iv17-iv21.

Centers for disease control and pre- vention. Algorithm for testing S. au- reus with vancomycin (VA) Retrie ved on Saturday, August 18, 2012 from http://www.cdc.gov/HAI/pdfs/visa_v rsa/VRSA_testing_algo2010.pdf.

Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al. The role of nasal carriage in Staphylococcus aureus in- fections. Lancet Infect Dis 2005; 5 (12): 751-62.

How to Cite
Askari E, Zarifian A, Pourmand M, Naderi-Nasab M. High-Level Vancomycin-Resistant Staphylococcus aureus (VRSA) in Iran: A Systematic Review. J Med Bacteriol. 1(3-4):53-61.
Review Articles